In honor of this month being named in honor of the Roman deity of looking backward and forward, my posts concerning veridictions (my process of verifying predictions) continues.
Today’s episode comes from the pages of WIRED magazine (the January 2012 issue to be exact) and its article entitled, “Trials and Errors” by Jonah Lehrer.
The opening paragraph of the article describes a moment in November of 2006 when the then-CEO of Pfizer, Jeff Kindler, made the announcement that torcetrapib, a Pfizer drug that had recently entered Phase III trials, would be “one of the most important compounds of our generation.”
Never heard of torcetrapib or of its revolutionary way it helps people with high cholesterol?
That’s because two days after Kindler’s bold prediction, (continuing from Lehrer’s article) Pfizer announced it was terminating the Phase III trials due to an increased rate of chest pain, heart failure, and mortality among participants.